It was a recombinant Ad-p53 that was the first commercialised gene therapy for cancer [45], and there has been a renewed interest in AV vectors despite initial setbacks, with their use accounting for 50% of global gene therapy trials to date, largely in vaccines and cancer therapies. Here, TP53 is linked to cancer.